# Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)

> **NCT05916326** · PHASE3 · COMPLETED · sponsor: **National Vaccine and Serum Institute, China** · enrollment: 8000 (actual)

## Conditions studied

- Norovirus Infections
- Norwalk Gastroenteritis

## Interventions

- **BIOLOGICAL:** Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT05916326
- **Lead sponsor:** National Vaccine and Serum Institute, China
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-30
- **Primary completion:** 2025-07-27
- **Final completion:** 2025-07-27
- **Target enrollment:** 8000 (ACTUAL)
- **Last updated:** 2026-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05916326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05916326, "Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05916326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*